PBYI - PUMA BIOTECHNOLOGY, INC.
IEX Last Trade
3.04
0.540 17.763%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$2.50
0.54
21.60%
Fundamental analysis
33%
Profitability
55%
Dept financing
23%
Liquidity
26%
Performance
16%
Performance
5 Days
9.82%
1 Month
0 0%
3 Months
18.43%
6 Months
2.03%
1 Year
-26.70%
2 Year
-24.12%
Key data
Stock price
$3.04
DAY RANGE
$2.50 - $2.92
52 WEEK RANGE
$2.35 - $7.73
52 WEEK CHANGE
-$30.41
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Alan H. Auerbach
Region: US
Website: pumabiotechnology.com
Employees: 200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: pumabiotechnology.com
Employees: 200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Puma Biotechnology, Inc. focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd.
Recent news